Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Gina Mazzariello Sells 4,169 Shares

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insider Gina Mazzariello sold 4,169 shares of Amylyx Pharmaceuticals stock in a transaction on Monday, February 24th. The shares were sold at an average price of $3.15, for a total value of $13,132.35. Following the completion of the sale, the insider now directly owns 134,921 shares of the company’s stock, valued at $425,001.15. This trade represents a 3.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Gina Mazzariello also recently made the following trade(s):

• On Monday, February 3rd, Gina Mazzariello sold 3,678 shares of Amylyx Pharmaceuticals stock. The shares were sold at an average price of $3.49, for a total value of $12,836.22.

Amylyx Pharmaceuticals Stock Up 4.6 %

Amylyx Pharmaceuticals stock opened at $3.20 on Thursday. Amylyx Pharmaceuticals, Inc. has a twelve month low of $1.58 and a twelve month high of $19.95. The company has a 50 day moving average of $3.63 and a 200-day moving average of $3.82. The stock has a market capitalization of $219.35 million, a PE ratio of -0.84 and a beta of -0.54.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Baird R W raised Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Amylyx Pharmaceuticals in a research note on Thursday, December 5th. Finally, Robert W. Baird raised shares of Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $3.00 to $11.00 in a research report on Monday, November 18th. Five analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $7.33.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Blue Trust Inc. boosted its position in shares of Amylyx Pharmaceuticals by 232.1% during the fourth quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock worth $26,000 after buying an additional 4,883 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in Amylyx Pharmaceuticals by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,094 shares of the company’s stock worth $42,000 after acquiring an additional 5,104 shares during the last quarter. XTX Topco Ltd grew its stake in shares of Amylyx Pharmaceuticals by 12.0% during the 4th quarter. XTX Topco Ltd now owns 53,376 shares of the company’s stock worth $202,000 after acquiring an additional 5,704 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Amylyx Pharmaceuticals by 11.8% in the fourth quarter. Northern Trust Corp now owns 106,564 shares of the company’s stock valued at $403,000 after purchasing an additional 11,214 shares during the last quarter. Finally, Fox Run Management L.L.C. bought a new stake in shares of Amylyx Pharmaceuticals in the fourth quarter worth $45,000. 95.84% of the stock is owned by institutional investors and hedge funds.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.